Capital, Competition and the Patent Cliff

A webinar preview of the dealmakers’ dialogue at the US Pharma & Biotech Summit

Webinar | March 18, 2026 | 12:00 – 12:50 PM ET

The patent cliff is coming, and big pharma is running out of time to get ahead of it.

With an estimated $180 billion in drug revenues set to lose protection in 2027–28, dealmaking isn't just heating up — it's on pace for a record year. Bidding wars are intensifying, premiums are climbing and capital markets are finally thawing after one of the worst biotech IPO droughts in over a decade. Add in drug pricing headwinds and a more permissive antitrust environment, and the strategic calculus has shifted fast.

On March 18, Endpoints Editor Drew Armstrong and FT’s Patrick Temple-West and Oliver Barnes will unpack what's really driving the action — in a preview webinar kicking off the Dealmakers' Dialogue at the US Pharma & Biotech Summit.

Join us online to get the latest on what's fueling pharma's dealmaking frenzy — and what comes next.

Registration is free.